Sodium Lactate 0.167 Molar In Plastic Container
(Sodium Lactate)Phase 2Small molecule
PfizerSodium Lactate 0.167 Molar In Plastic Container is one of 127 small molecule programs targeting Cardiac Arrest. It is currently in Phase 2.
4
Indications
9
Total Trials
4
Active Trials
126
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
115 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Celexa
AbbVieApproved
Cialis
Eli LillyApproved
Lamictal
GGlaxo Dba Glaxosmithkline
Approved
Transderm Scop
BBaxter Healthcare Corporation
Approved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Clozaril
LLife Extension Foundation Inc.
Phase 3
Psilocybin
COMPASS PathwaysPhase 3
Ssris
Eli LillyPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypoglycemia2 trials
AIN1 trial
Sodium Lactate and Brain Relaxation (LSD)
Completed·—·Phase 3·NCT04488874·50 enrolled
Major Depressive Disorder1 trial
Feasibility of Conducting a Clinical Trial Assessing Efficacy of Lactate as Adjunctive Therapy in Patients With Major Depressive Disorder
Not yet recruiting·—·Phase 2·NCT06168175·46 enrolled
3 more indications
Sepsis1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER
NDA NDA018186
Jan 1, 1982
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER
NDA NDA016692
Jan 1, 1982
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER
NDA NDA018249
Sep 5, 1984
SODIUM LACTATE IN PLASTIC CONTAINER
NDA NDA018947
Apr 21, 1992
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER
NDA NDA020004
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sodium Lactate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]